Search
-
Luye Pharma’s Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao
A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Pharma Group (Luye Pharma) took place i...
2024-03-07
MORE>
-
Boan Biotech Obtains ANVISA GMP Certification
Boan Biotech announced today that it has received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA) for its biological product, Boyuno®(Bevacizu...
2024-01-18
MORE>
-
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
December 27, 2023 -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer ...
2023-12-28
MORE>
-
Luye Pharma’s Innovative Formulations Baituowei and Rykindo Included on China’s 2023 National Reimbursement Drug List
December 13, 2023– Luye Pharma Group today announced that two of its in-house developed innovative formulations have been included on the National Reimbursement Drug List for Basic Medical Insur...
2023-12-13
MORE>
-
Luye Diagnostics Announces the Approval of Great Basin Toxigenic C. difficile Direct Test (CDF2) in the US
December 13, 2023 -- Luye Diagnostics Group today announced that Great Basin Toxigenic C. difficile Direct Test (CDF2), independently developed by Vela Operations USA, has been approved by U.S. Food a...
2023-12-13
MORE>
-
Luye Pharma Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong
Lurbinectedin is a new chemical compound with a novel mechanism of action. It’s been the only new chemical entity approved by the U.S. FDA for the treatment of relapsed SCLC over the past 26 yea...
2023-12-04
MORE>
-
Luye Pharma Subsidiary WPU Signs MoU with AstraZeneca Brazil and Herbarium at CIIE for Marketing Xuezhikang in Brazil
The 6th China International Import Expo (CIIE) kicked off on November 5th, 2023. With its spillover effect, the CIIE provides a major platform for the internationalization of Traditional Chinese Medic...
2023-11-09
MORE>
-
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
Shanghai, October 31, 2023 -- Luye Pharma Group today announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Adm...
2023-11-01
MORE>
-
NDA for Luye Pharma’s Paliperidone Palmitate Extended-release Injectable Suspension Submitted in the U.S.
Shanghai, October 9, 2023 - Luye Pharma Group today announced the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway for its LY03...
2023-10-09
MORE>
-
Luye Pharma Ltd Launches New Alzheimer's Treatment In The UK
Luye Pharma Ltd, a subsidiary of Luye Pharma Group has launched an innovative new product for the treatment of Alzheimer's disease.Zeyzelf® twice weekly rivastigmine transdermal patch is for the s...
2023-10-07
MORE>
var _hmt = _hmt || [];
(function() {
var hm = document.createElement("script");
hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864";
var s = document.getElementsByTagName("script")[0];
s.parentNode.insertBefore(hm, s);
})();
!function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
one体育-艾尚体育
沐鸣平台_沐鸣平台科技_沐鸣平台厂家_沐鸣平台企业
力量体育app_官网-力量体育app
one体育-官网app下载
im电竞官网app